Partial hepatic resistance to IL-6-induced inflammation develops in type 2 diabetic mice, while the anti-inflammatory effect of AMPK is maintained

Molecular and Cellular Endocrinology

Volumn 393, Issue 1-2, 2014, Pages 143-151

  Cansby, Emmelie ^a   Nerstedt, Annika ^a   Amrutkar, Manoj ^a   Durán, Esther Nuñez ^a   Smith, Ulf ^a   Mahlapuu, Margit ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

AMPK; IL 6; Inflammation; Liver; Type 2 diabetes

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METFORMIN; STAT3 PROTEIN; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ANTIINFLAMMATORY AGENT; GLUCOSE BLOOD LEVEL; RIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE REPRESSION; GLUCOSE INTOLERANCE; HEPATITIS; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID DIET; LIVER CELL; MALE; MOUSE; MOUSE MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; GLUCOSE BLOOD LEVEL; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-6; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEOTIDES;

EID: 84904045056     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.06.014     Document Type: Article

References (64)

1. Akerfeldt M.C., Laybutt D.R. Inhibition of Id1 augments insulin secretion and protects against high-fat diet-induced glucose intolerance. Diabetes 2011, 60:2506-2514.
2. Al-Khalili L., Bouzakri K., Glund S., Lonnqvist F., Koistinen H.A., Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol. Endocrinol. 2006, 20:3364-3375.
3. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation (correction of activation) in the liver. Mol. Cell. Biol. 2001, 21:1621-1632.
4. Bastard J.P., Maachi M., Van Nhieu J.T., Jardel C., Bruckert E., Grimaldi A., Robert J.J., Capeau J., Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 2002, 87:2084-2089.
5. Begue J.M., Guguen-Guillouzo C., Pasdeloup N., Guillouzo A. Prolonged maintenance of active cytochrome P-450 in adult rat hepatocytes co-cultured with another liver cell type. Hepatology 1984, 4:839-842.
6. Campos S.P., Wang Y., Baumann H. Insulin modulates STAT3 protein activation and gene transcription in hepatic cells. J. Biol. Chem. 1996, 271:24418-24424.
7. Cansby E., et al. Increased expression of STK25 leads to impaired glucose utilization and insulin sensitivity in mice challenged with a high-fat diet. Fed. Proc. 2013, 27:3660-3671.
8. Carey A.L., et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006, 55:2688-2697.
9. Carling D. AMP-activated protein kinase: balancing the scales. Biochimie 2005, 87:87-91.
10. Carling D., Mayer F.V., Sanders M.J., Gamblin S.J. AMP-activated protein kinase: nature's energy sensor. Nat. Chem. Biol. 2011, 7:512-518.
11. Carlsson L., Nilsson I., Oscarsson J. Hormonal regulation of liver fatty acid-binding protein in vivo and in vitro: effects of growth hormone and insulin. Endocrinology 1998, 139:2699-2709.
12. Chen M.B., McAinch A.J., Macaulay S.L., Castelli L.A., O'Brien P.E., Dixon J.B., Cameron-Smith D., Kemp B.E., Steinberg G.R. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J. Clin. Endocrinol. Metab. 2005, 90:3665-3672.
13. Clayton D.F., Darnell J.E. Changes in liver-specific compared to common gene transcription during primary culture of mouse hepatocytes. Mol. Cell. Biol. 1983, 3:1552-1561.
14. Davis R.C., et al. Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes 2010, 59:1616-1625.
15. Febbraio M.A., Pedersen B.K. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. Fed. Proc. 2002, 16:1335-1347.
16. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 2004, 279:16154-16160.
17. Hattori Y., Suzuki K., Hattori S., Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47:1183-1188.
18. Homan R., Anderson M.K. Rapid separation and quantitation of combined neutral and polar lipid classes by high-performance liquid chromatography and evaporative light-scattering mass detection. J. Chromatogr. B Biomed. Sci. Appl. 1998, 708:21-26.
19. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
20. Huang L., Kirschke C.P., Lay Y.A., Levy L.B., Lamirande D.E., Zhang P.H. Znt7-null mice are more susceptible to diet-induced glucose intolerance and insulin resistance. J. Biol. Chem. 2012, 287:33883-33896.
21. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2364-2367.
22. Iglesias M.A., Ye J.M., Frangioudakis G., Saha A.K., Tomas E., Ruderman N.B., Cooney G.J., Kraegen E.W. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002, 51:2886-2894.
23. Jelen S., Wacker S., Aponte-Santamaria C., Skott M., Rojek A., Johanson U., Kjellbom P., Nielsen S., de Groot B.L., Rutzler M. Aquaporin-9 protein is the primary route of hepatocyte glycerol uptake for glycerol gluconeogenesis in mice. J. Biol. Chem. 2011, 286:44319-44325.
24. Jiang L.Q., Duque-Guimaraes D.E., Machado U.F., Zierath J.R., Krook A. Altered response of skeletal muscle to IL-6 in type 2 diabetic patients. Diabetes 2013, 62:355-361.
25. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E745-E751.
26. Kim Y.D., Kim Y.H., Cho Y.M., Kim D.K., Ahn S.W., Lee J.M., Chanda D., Shong M., Lee C.H., Choi H.S. Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 2012, 55:1482-1494.
27. Klover P.J., Zimmers T.A., Koniaris L.G., Mooney R.A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003, 52:2784-2789.
28. Lemmers A., et al. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. Clin. Exp. Immunol. 2009, 156:518-527.
29. Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 2006, 116:1776-1783.
30. Mansouri R.M., Bauge E., Staels B., Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology 2008, 149:3215-3223.
31. Meng R., Zhu D.L., Bi Y., Yang D.H., Wang Y.P. Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice. Mediators Inflamm. 2010, 2010:858735.
32. Mukumoto H., Takahashi Y., Ando M., Nishikawa M., Takakura Y. Expression profile-dependent improvement of insulin sensitivity by gene delivery of interleukin-6 in a mouse model of type II diabetes. Mol. Pharm. 2013, 10:3812-3821.
33. Nerstedt A., Johansson A., Andersson C.X., Cansby E., Smith U., Mahlapuu M. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 2010, 53:2406-2416.
34. Nerstedt A., Cansby E., Amrutkar M., Smith U., Mahlapuu M. Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes. Mol. Cell. Endocrinol. 2013, 375:68-78.
35. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
36. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
37. Ramadoss P., Unger-Smith N.E., Lam F.S., Hollenberg A.N. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol. Endocrinol. 2009, 23:827-837.
38. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994, 300(Pt 2):281-290.
39. Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 2003, 278:45777-45784.
40. Sag D., Carling D., Stout R.D., Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181:8633-8641.
41. Sakamoto K., Goransson O., Hardie D.G., Alessi D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E310-E317.
42. Salhanick A.I., Konowitz P., Amatruda J.M. Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats. Diabetes 1983, 32:206-212.
43. Satoh T., Nakamura S., Taga T., Matsuda T., Hirano T., Kishimoto T., Kaziro Y. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol. Cell. Biol. 1988, 8:3546-3549.
44. Scheele C., Nielsen S., Kelly M., Broholm C., Nielsen A.R., Taudorf S., Pedersen M., Fischer C.P., Pedersen B.K. Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6. PLoS ONE 2012, 7:e39657.
45. Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
46. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., Mooney R.A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278:13740-13746.
47. Serrano A.L., Baeza-Raja B., Perdiguero E., Jardi M., Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008, 7:33-44.
48. Song X.M., Fiedler M., Galuska D., Ryder J.W., Fernstrom M., Chibalin A.V., Wallberg-Henriksson H., Zierath J.R. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002, 45:56-65.
49. Steward A.R., Dannan G.A., Guzelian P.S., Guengerich F.P. Changes in the concentration of seven forms of cytochrome P-450 in primary cultures of adult rat hepatocytes. Mol. Pharmacol. 1985, 27:125-132.
50. Su X., Gi Y.J., Chakravarti D., Chan I.L., Zhang A., Xia X., Tsai K.Y., Flores E.R. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab. 2012, 16:511-525.
51. Szalai A.J., van Ginkel F.W., Dalrymple S.A., Murray R., McGhee J.R., Volanakis J.E. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J. Immunol. 1998, 160:5294-5299.
52. Taga T., Kawanishi Y., Hardy R.R., Hirano T., Kishimoto T. Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J. Exp. Med. 1987, 166:967-981.
53. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573-581.
54. Torisu T., Sato N., Yoshiga D., Kobayashi T., Yoshioka T., Mori H., Iida M., Yoshimura A. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007, 12:143-154.
55. Ueki K., Kondo T., Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 2004, 24:5434-5446.
56. Ueki K., Kondo T., Tseng Y.H., Kahn C.R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 2004, 101:10422-10427.
57. Vieira E., Nilsson E.C., Nerstedt A., Ormestad M., Long Y.C., Garcia-Roves P.M., Zierath J.R., Mahlapuu M. Relationship between AMPK and the transcriptional balance of clock-related genes in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1032-E1037.
58. Wallerstedt E., Sandqvist M., Smith U., Andersson C.X. Anti-inflammatory effect of insulin in the human hepatoma cell line HepG2 involves decreased transcription of IL-6 target genes and nuclear exclusion of FOXO1. Mol. Cell. Biochem. 2011, 352:47-55.
59. Wang Y., Kinzie E., Berger F.G., Lim S.K., Baumann H. Haptoglobin, an inflammation-inducible plasma protein. Redox Rep. 2001, 6:379-385.
60. Weigert C., Hennige A.M., Brodbeck K., Haring H.U., Schleicher E.D. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am. J. Physiol. Endocrinol. Metab. 2005, 289:E251-E257.
61. Wieckowska A., Papouchado B.G., Li Z., Lopez R., Zein N.N., Feldstein A.E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008, 103:1372-1379.
62. Yudkin J.S., Panahloo A., Stehouwer C., Emeis J.J., Bulmer K., Mohamed-Ali V., Denver A.E. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 2000, 43:1099-1106.
63. Zhao X., Zmijewski J.W., Lorne E., Liu G., Park Y.J., Tsuruta Y., Abraham E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L497-L504.
64. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.